Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Dr Lalchandani Labs Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹7.76 |
|---|---|
| Day's Range | ₹7.33 - ₹7.77 |
| Open | ₹7.77 |
| 52 Week Range | ₹06.46 - ₹21.22 |
| Volume | 16,000 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.21 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 106.39 |
| TTM EPS (₹) | 0.07 |
| P/E Ratio | 10.61 |
| Book Value(₹) | 0.47 |
| PAT Margin (%) | 9.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 3.61 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 44.54 |
| Expenses | N/A | N/A |
| PBT | N/A | 4.02 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 4.17 |
About Dr Lalchandani Labs Ltd.
| Founded | 2011 |
|---|---|
| Managing Director | Arjan Lalchandani |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,80,046.94 | 2,007.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,08,140.64 | 7,840.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,263.87 | 4,870.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,29,210.64 | 8,986.40 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,430.12 | 1,464.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,271.55 | 1,113.75 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,609.69 | 2,422.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,09,639.25 | 1,124.65 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,06,427.00 | 2,576.95 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 97,942.13 | 563.35 | 0.00 - 0.00 |
No Records Found
Latest News
Jul
30
2026
Posted on Jul 30th 2026
Hester Biosciences informs about financial results
Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved the unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026, as recommended by Audit Committee. The company has attached: approved unaudited standalone and consolidated financial results and limited review reports; and a Press Release issued in this regard. The company will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 am (IST) and concluded at 11:07 am (IST).
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Chandra Bhagat Pharma submits board meeting intimation
Chandra Bhagat Pharma has informed that pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors (Board Meeting) of Chandra Bhagat Pharma (the Company) is scheduled to be held on Wednesday 5th August, 2026, to increasing in Authorised Share Capital of Company; to consider a proposal of fund raising by issue of Equity Shares/ convertible warrants and/or any other instruments through Preferential allotment towards consideration for cash or other than cash, subject to approval of shareholders and compliances of applicable provision of law; to fix the date, time, place for holding the Extra Ordinary General Meeting (EOGM) for obtaining shareholders’ approval for aforesaid preferential issue and other agenda items; and any other business with the permission of the chair which is incidental and ancillary to the business. Pursuant to the Code of Conduct for prevention of insider trading (the Code of Conduct), framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window for dealing in the securities shall remain closed for all connected persons / officers / designated employees / insiders, directors of the Company and immediate relatives of these persons, including but not limited to the persons specified in the Company's Code of Conduct from 30th July, 2026 till the end of 48 hours from the conclusion of the Board Meeting.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Hester Biosciences informs about outcome of board meeting
With reference to the letter dated 23 July 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter ended 30 June 2026 and pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that the Board of Directors, in their Meeting held today, have approved the unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026, as recommended by Audit Committee. Attached the approval of unaudited standalone and consolidated financial results and limited review reports; A Press Release issued in this regard. Thet will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 am (IST) and concluded at 11:07 am (IST).
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Aurobindo Pharma informs about press release
Aurobindo Pharma has informed that it enclosed copies of the Notice published in the newspapers, Business Standard and Nava Telangana on July 30, 2026, intimating the shareholders that the 39th Annual General Meeting of the Company will be held on Thursday, August 27, 2026, at 3:30 pm (IST) through Video Conferencing / Other Audio-Visual Means.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Goldline Pharmaceutical informs about disclosure
Goldline Pharmaceutical has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr Lalchandani Labs Ltd. is ₹7.76 as of 2026-07-30.
The market capitalisation of Dr Lalchandani Labs Ltd. is ₹6.70 as of 2026-07-30.
The 1-year return of Dr Lalchandani Labs Ltd. is % as of .
The P/E ratio of Dr Lalchandani Labs Ltd. is 10.61 as of 2026-07-31.
The 52-week high and low of Dr Lalchandani Labs Ltd. are ₹21.22 and ₹6.46, respectively, as of 2026-07-30.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
